Ignite Creation Date:
2025-12-25 @ 2:06 AM
Ignite Modification Date:
2025-12-26 @ 5:54 AM
Study NCT ID:
NCT06284460
Status:
WITHDRAWN
Last Update Posted:
2024-10-24
First Post:
2024-02-21
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms
Sponsor:
M.D. Anderson Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-01-31
Start Date Type:
ESTIMATED
Primary Completion Date:
2025-12-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-12-01
Completion Date Type:
ESTIMATED
First Submit Date:
2024-02-21
First Submit QC Date:
None
Study First Post Date:
2024-02-29
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-22
Last Update Post Date:
2024-10-24
Last Update Post Date Type:
ACTUAL